2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

  • Valentin Ritschl, Medical University Vienna, Vienna
  • ,
  • Tanja A Stamm, Medical University Vienna, Vienna
  • ,
  • Daniel Aletaha, Medical University Vienna, Vienna
  • ,
  • Johannes W J Bijlsma, Pediatric Rheumatology, PRI - Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany
  • ,
  • Peter Böhm, Deutsche Rheuma-Liga Bundesverband e.V
  • ,
  • Razvan Gabriel Dragoi, Department of Microscopic Morphology/Histology, Angiogenesis Research Center, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania.
  • ,
  • Emma Dures, The University of the West of England
  • ,
  • Fernando Estévez-López, Erasmus University Medical Center Cancer Institute, Department of Obstetrics and Gynaecology, Erasmus University Medical Center.
  • ,
  • Laure Gossec, Institut Pierre Louis d'Epidémiologie et de Santé Publique
  • ,
  • Annamaria Iagnocco, Scienze Cliniche e Biologiche
  • ,
  • Andrea Marques, CENTRO HOSPITALAR E UNIVERSITARIO DE COIMBRA E.P.E.
  • ,
  • Ellen Moholt, Diakonhjemmet Hospital
  • ,
  • Michal Nudel, Mifrakim Tz'eirim
  • ,
  • Bart J F van den Bemt, Department of Pharmacy Practice and Clinical Pharmacy, School of Pharmacy, University of Ghana, Legon, Ghana.
  • ,
  • Kirsten Viktil, Hospital Pharmacy, Aarhus University Hospital, Aarhus
  • ,
  • Marieke Voshaar, Twente University
  • ,
  • Annette de Thurah
  • Loreto Carmona, Instituto de Salud Musculoesquelética (INMUSC)

BACKGROUND: Non-adherence to treatment could preclude reaching an optimal outcome. Thirty to 80% of patients with rheumatic and musculoskeletal diseases (RMDs) do not adhere to the agreed treatment.

OBJECTIVES: The objective was to establish points to consider (PtCs) for the prevention, screening, assessment and management of non-adherence to (non-)pharmacological treatments in people with RMDs.

METHODS: An EULAR task force (TF) was established, and the EULAR standardised operating procedures for the development of PtCs were followed. The TF included healthcare providers (HCPs), comprising rheumatologists, nurses, pharmacists, psychologists, physiotherapists, occupational therapists and patient-representatives from 12 European countries. A review of systematic reviews was conducted in advance to support the TF in formulating the PtCs. The level of agreement among the TF was established by anonymous online voting.

RESULTS: Four overarching principles and nine PtCs were formulated. The PtCs reflect the phases of action on non-adherence. HCPs should assess and discuss adherence with patients on a regular basis and support patients to treatment adherence. As adherence is an agreed behaviour, the treatment has to be tailored to the patients' needs. The level of agreement ranged from 9.5 to 9.9 out of 10.

CONCLUSIONS: These PtCs can help HCPs to support people with RMDs to be more adherent to the agreed treatment plan. The basic scheme being prevent non-adherence by bonding with the patient and building trust, overcoming structural barriers, assessing in a blame-free environment and tailoring the solution to the problem.

OriginalsprogEngelsk
TidsskriftAnnals of the Rheumatic Diseases
ISSN0003-4967
DOI
StatusE-pub ahead of print - 18 dec. 2020

Se relationer på Aarhus Universitet Citationsformater

ID: 206773294